Involvement of NF-κB Signaling Pathway in the Pathogenesis of Systemic Lupus Erythematosus
DOI:
https://doi.org/10.17140/NPOJ-2-112Keywords:
Systemic lupus erythematosus (SLE); Nuclear factor kappa binding (NF-κB); Lupus; Toll-like receptors (TLRs).Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by accumulation of anti-nuclear autoantibodies, hyperactivation. It can affect any organ, including
brain, skin, joint, and kidney. The nuclear NF-κB pathway has long been considered a crucial
pro- inflammatory signaling pathway. Its transcribed the genes involves in various autoimmune
disease. Within the past year, many research studies have been conducted the role of NF-κB
signaling in lupus. In this review, we will highlight some recent studies that support the potential link of NF-κB signaling pathway which play a crucial role in the pathogenesis of SLE.
References
James JA, Gross T, Scofield RH, Harley JB. Immunoglobulin epitope spreading and autoimmune disease after peptide immu-nization. J Exp Med. 1995; 181(2): 453-461. Web site. http://jem. rupress.org/content/181/2/453.long. Accessed April 19, 2016
Linker-Israeli M, Deans RJ, Wallace DJ, et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A puta-tive role in pathogenesis. J Immunol. 1991; 147(1): 117-123. Web site. http://www.jimmunol.org/content/147/1/117.long. Ac-cessed April 19, 2016
Fernandez-Gutierrez B, de Miguel S, Morado C, et al. De-fective early T and T-dependent B-cell activation in sys-temic lupus erythematosus. Lupus. 1998; 7(5): 314-322. doi: 10.1191/096120398678920226
Tiruppathi C, Soni D, Wang D-M, et al. The transcription fac-tor DREAM represses the deubiquitinase A20 and mediates in-flammation. Nat Immunol. 2014; 15(3): 239-247. doi: 10.1038/ ni.2823
Lewis MJ. UBE2L3 polymorphism amplifies NF-κB activa-tion and promotes plasma cell development, linking linear ubiq-uitination to multiple autoimmune diseases. Am J Hum Genet. 2015; 96(2): 221-234. doi: 10.1016/j.ajhg.2014.12.024
Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol. 2007; 18(6): 1721-1731. doi: 10.1681/ASN.2006101162
Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Im-munol. 2004; 4: 499-511. doi: 10.1038/nri1391
Sun D, Ding A. MyD88-mediated stabilization of interferon-gamma-induced cytokine and chemokine mRNA. Nat Immunol. 2006; 7(4): 375-381. doi: 10.1038/ni1308
Honda K, Takaoka A, Taniguchi T. Type I interferon gene in-duction by the interferon regulatory factor family of transcrip-tion factors. Immunity. 2006; 25(3): 349-360. doi: 10.1016/j. immuni.2006.08.009
Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003; 21: 335-376. doi: 10.1146/annurev.immu-nol.21.120601.141126
Bekeredjian-Ding I, Doster A, Schiller M, et al. TLR9-acti-vating DNA up-regulates ZAP70 via sustained PKB induction in IgM+ B-cells. J Immunol. 2008; 181(12): 8267-8277. doi: 10.4049/jimmunol.181.12.8267
Akira T, Takeda K, Kaisho T. Toll-like receptors: proteins linking innate and acquired immunity. Nat Immunol. 2001; 2(8): 675-680. doi: 10.1038/90609
Theofilopouluos AN, Gonzalez-Quintal R, Lawson BR, et al. Sensors of innate immune system; their link to rheumatic dis-eases. Nat Rev Rheumatol. 2010; 6(3): 146-156. doi: 10.1038/ nrrheum.2009.278
Richez C, Blanco P, Rifkin I, Moreau JK, Schaeverbeke T. Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint Bone Spine. 2011; 78(2): 124-130. doi: 10.1016/j.jbspin.2010.09.005
Hurst J, von Landenberg P. Toll-like receptors and autoim-munity. Autoimmun Rev. 2008; 7(3): 204-208. doi: 10.1016/j. autrev.2007.11.006
Bijil M, Limburg PC, Kallenberg CGM. New insights into the pathogenesis of systemic lupus erythematosus (SLE); the role of apoptosis. Neth J Med. 2001; 59(2): 66-75. doi: 10.1016/ S0300-2977(01)00131-0
Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complex-es activate B-cells by dual engagement of IgM and Toll like recep-tors. Nature. 2002; 416(6881): 603-607. doi: 10.1038/416603a
Christensen SR, Shupe J, Nickerson K, Kashgarian M, Fla-vell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006; 25(3): 417-428. doi: 10.1016/j.immuni.2006.07.013
Kirou KA, Lee C, George S, Louca K, Peterson MGE, Crow MK. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005; 52(5): 1491- 1503. doi: 10.1002/art.21031
Zhang W. Aberrant CD40-Induced NF-κB Activation in Hu-man Lupus B Lymphocytes. PLoS One. 2012; 7(8): e41644. doi: 10.1371/journal.pone.0041644
Pacheco GV, Irene B, Noh N, et al. Expression of TLR-7, MyD88, NF-κB, and INF-α in B lymphocytes of mayan women with systemic lupus erythematosus in Mexico. Front Immunol. 2016; 7: 22. doi: 10.3389/fimmu.2016.00022
Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010; 327(5963): 291- 295. doi: 10.1126/science.1183021
Zhou J, Wu R, High AA, et al. A20-binding inhibitor of NF-κB (ABIN1) controls Toll-like receptor-mediated CCAAT/ enhancer-binding protein β activation and protects from inflam-matory disease. Proc Natl Acad Sci U S A. 2011; 108(44): E998- E1006. doi: 10.1073/pnas.1106232108
Enzler T, Bonizzi G, Silverman GJ, et al. Alternative and classical NF-kappa B signaling retain autoreactive B-cells in the splenic marginal zone and result in lupus-like disease. Immunity. 2006; 25(3): 403-415. doi: 10.1016/j.immuni.2006.07.010
Lee YH, Choi SJ, Ji JD, Song GG. Association between toll-like receptor polymorphisms and systemic lupus erythemato-sus: a meta-analysis update. Lupus. 2016; 25(6): 593-601. doi: 10.1177/0961203315622823
Rullo OJ, Tsao BP. Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis. 2013; 72 Suppl 2: ii56-61. doi: 10.1136/annrheumdis-2012-202351
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Nephrology (NOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.